HTG Molecular Diagnostics, Inc. and OmiCure® announced a collaboration with OmiCure to implement the HTG Transcriptome Panel (HTP) as an alternative to RNA-Seq to inform the OmiCure test and help guide therapeutic decision-making across several cancer types. Through this collaboration, samples collected by OmiCure will be sent to HTG's VERI/O® laboratory in Tucson, Arizona for processing. Data generated with HTP will be analyzed by OmiCure using the robust OmiCure AI platform Onco KEM® for reporting to requesting healthcare providers.

HTP utilizes the proprietary HTG EdgeSeq® system, requiring only a fraction of the tissue biopsy material used by other systems to analyze nearly 20,000 genes. HTG EdgeSeq's comprehensive gene expression data can be available in as few as three days, far faster than more conventional methods like RNA-Seq, and is less dependent on sample quality. OmiCure leverages Onco KEM, an AI-transcriptional-based therapeutic recommendation-tool, which has been tested in an international multi-center clinical trial.

This technology matches patients' tumor RNA profiles with comprehensive databases of existing therapies and scores them according to their potential actions.